{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:06:07Z","timestamp":1790082367874,"version":"4.0.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context:<\/jats:title>\n                    <jats:p>Mitoxantrone (MTX) is an antracyclin drug that is used for treatment of patients with chronic refractory multiple sclerosis (MS). Congestive heart failure (CHF) is a rare complication of this drug that may occur early, during therapy, or late, months or years after termination of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>The aim of this study is to evaluate the long-term adverse effect of MTX on cardiac function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The study involved 49 MS patients on MTX therapy because of their disease was refractory to other treatments (18 men and 31 women). They were treated in two canters related to Esfahan University of Medical Sciences. The mean age was 34.65 \u00b1 9.56 years. Systolic and diastolic left ventricular (LV) functions were measured by echocardiography. The baseline echocardiographic data were collected from patients' file. Echocardiography was repeated by a single cardiologist in 2016.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      After MTX therapy, one patient's ejection fraction (EF) reduced below 50% (2%). In spite of their normal diastolic function before therapy, two patients developed diastolic dysfunction (4%). Nonparametric binominal analysis reveals that MTX therapy increased the probability of developing systolic dysfunction, early or late\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 001.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>MS patients treated with MTX are at increased risk of developing early and late-LV dysfunction, so all patients on MTX therapy must be periodically evaluated for these late complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijpvm.ijpvm_477_17","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T05:46:45Z","timestamp":1578548805000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Late Cardiotoxicity in MS Patients Treated with Mitoxantrone"],"prefix":"10.4103","volume":"10","author":[{"given":"Jamshid","family":"Najafian","sequence":"first","affiliation":[{"name":"Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Nasri","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Etemadifar","sequence":"additional","affiliation":[{"name":"Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fardin","family":"Salehzadeh","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical School, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"R1-20250812","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/jnnp.62.2.112","article-title":"Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria","volume":"62","author":"Edan","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R2-20250812","first-page":"66","article-title":"Mitoxantrone role in treatment of primary progressive multiple sclerosis","volume":"40","author":"Pastuszak","year":"2016","journal-title":"Pol Merkur Lekarski"},{"key":"R3-20250812","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"key":"R4-20250812","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0046-8177(98)90395-1","article-title":"HLA-DR-positive dendritic cells of the normal human choroid plexus: A potential reservoir of HIV in the central nervous system","volume":"29","author":"Hanly","year":"1998","journal-title":"Hum Pathol"},{"key":"R5-20250812","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00018-016-2170-9","article-title":"Dendritic cells as therapeutic targets in neuroinflammation","volume":"73","author":"Luessi","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"R6-20250812","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s004150050066","article-title":"Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome","volume":"244","author":"Millefiorini","year":"1997","journal-title":"J Neurol"},{"key":"R7-20250812","first-page":"210","article-title":"A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis","volume":"101","author":"van de Wyngaert","year":"2001","journal-title":"Acta Neurol Belg"},{"key":"R8-20250812","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/00023210-200418060-00010","article-title":"Mitoxantrone: A review of its use in multiple sclerosis","volume":"18","author":"Scott","year":"2004","journal-title":"CNS Drugs"},{"key":"R9-20250812","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1212\/WNL.63.12_suppl_6.S28","article-title":"Mitoxantrone treatment of multiple sclerosis: Safety considerations","volume":"63","author":"Cohen","year":"2004","journal-title":"Neurology"},{"key":"R10-20250812","first-page":"609","article-title":"Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies","volume":"71","author":"Mather","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"R11-20250812","first-page":"111","article-title":"Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis","volume":"9","author":"Hamzehloo","year":"2006","journal-title":"Arch Iran Med"},{"key":"R12-20250812","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1191\/1352458503ms896oa","article-title":"Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis","volume":"9","author":"Avasarala","year":"2003","journal-title":"Mult Scler"},{"key":"R13-20250812","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1212\/WNL.59.6.909","article-title":"Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS","volume":"59","author":"Ghalie","year":"2002","journal-title":"Neurology"},{"key":"R14-20250812","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","article-title":"Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: Application to patients undergoing cancer chemotherapy","volume":"61","author":"Thavendiranathan","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R15-20250812","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/BF02191555","article-title":"Treatment of multiple sclerosis with mitoxantrone","volume":"242","author":"Mauch","year":"1992","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R16-20250812","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/jnnp.2006.091033","article-title":"Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis","volume":"78","author":"Paul","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R17-20250812","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3988\/jcn.2014.10.4.289","article-title":"Cardiotoxicity of mitoxantrone treatment in a German cohort of 639 multiple sclerosis patients","volume":"10","author":"Fleischer","year":"2014","journal-title":"J Clin Neurol"},{"key":"R18-20250812","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1471-2377-13-80","article-title":"Results from the 5-year, phase IV RENEW (Registry to evaluate novantrone effects in worsening multiple sclerosis) study","volume":"13","author":"Rivera","year":"2013","journal-title":"BMC Neurol"},{"key":"R19-20250812","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00204-016-1759-y","article-title":"Pathways of cardiac toxicity: Comparison between chemotherapeutic drugs doxorubicin and mitoxantrone","volume":"90","author":"Damiani","year":"2016","journal-title":"Arch Toxicol"},{"key":"R20-20250812","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline chemotherapy and cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"R21-20250812","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2004.06.033","article-title":"Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults","volume":"22","author":"Hequet","year":"2004","journal-title":"J Clin Oncol"},{"key":"R22-20250812","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jns.2004.04.018","article-title":"The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis","volume":"223","author":"Jeffery","year":"2004","journal-title":"J Neurol Sci"},{"key":"R23-20250812","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1517\/14740338.5.2.265","article-title":"The cardiac effects of mitoxantrone: Do the benefits in multiple sclerosis outweigh the risks?","volume":"5","author":"Murray","year":"2006","journal-title":"Expert Opin Drug Saf"}],"container-title":["International Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01439446-201910000-00209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:28:39Z","timestamp":1787837319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01439446-201910000-00209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.4103\/ijpvm.ijpvm_477_17","relation":{},"ISSN":["2008-7802","2008-8213"],"issn-type":[{"value":"2008-7802","type":"print"},{"value":"2008-8213","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"2017-11-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}